Medicinal aerosol formulations of formoterol

Details Medicinal aerosol formulations of formoterol Medicinal aerosol formulations of formoterol

1998-06-02

2000-04-25

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

A61K 31135

Patent

active

060544880

ABSTRACT:
A pharmaceutical suspension formulation suitable for aerosol administration having from 0.0025 to 0.1% w/w of micronized Formoterol, or an acid addition salt thereof, from 0.1 to 5.0% w/w ethanol, HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a, and optionally a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug.

REFERENCES:
patent: 2868691 (1959-01-01), Porush et al.
patent: 3014844 (1961-12-01), Thiel et al.
patent: 5182097 (1993-01-01), Byron et al.
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5439670 (1995-08-01), Purewal et al.
patent: 5605674 (1997-02-01), Purewal et al.
patent: 5653962 (1997-08-01), Akehurst et al.
patent: 5658549 (1997-08-01), Akehurst et al.
patent: 5674471 (1997-10-01), Akehurst et al.
patent: 5674473 (1997-10-01), Purewal et al.
patent: 5676929 (1997-10-01), Akehurst et al.
patent: 5681545 (1997-10-01), Purewal et al.
patent: 5683677 (1997-11-01), Purewal et al.
patent: 5695743 (1997-12-01), Purewal et al.
patent: 5720940 (1998-02-01), Purewal et al.
patent: 5736124 (1998-04-01), Akehurst et al.
patent: 5744123 (1998-04-01), Akehurst et al.
patent: 5766573 (1998-06-01), Purewal et al.
patent: 5776434 (1998-07-01), Purewal et al.
Kontny, M.J.; Destefano, G.; Jager, P.D.; McNamara, D.P.; Turi, J.S.; and Van Campen, L. "Issues Surrounding MDI Formulation Development with Non-CFC Propellants", Journal of Aerosol Medicine, vol. 4, No. 3, 1991, pp. 181-187, Mary Ann Liebert, Inc., Publishers.
Tansey, Ian P. "The challenges in the development of metered dose inhalation aerosols using ozon-friendly propellants", Spray Technology & Marketing for Jul. 1994, pp. 26-29.
Sharpe, R., "Development of a metered dose inhaler using one of the new HFA Propellants", Aerosol and SprayReport, vol. 35, No. 3/96, pp. 127-129.
Dalby, Richard N.; Byron, Peter R.,; Shepherd, H.R.; and Papadopoulos, Elaine, "CFC Propellant Substitution: P--134a as a Potential Replacement for P--12 in MDIs", Pharmaceutical Technology, Mar. 1990, pp.--26-33.
Jinks, P.A., "A Rapid Technique for Characterisation of the Suspension Dynamics of Metered Dose Inhaler Formulations", Proceedings of Drug Delivery to the Lung, VI P. 10-13 (Dec. 1995) printed by The Aerosol Society.
Phillips, Elaine M., "Crystal Growth--Formulation Dependence and Early Detection", Journal of Biopharmaceutical Sciences, 3(1/2) 1992, pp.--11-18.
Smith, Ian J. "The Challenge of Reformulation", Journal of Aerosol Medicine, vol. 8, Supplement 1, 1995, Mary Ann Liebert, Inc., Publishers, pp.--s-19--s-27.

Affiliated with

Also associated with

Rating

Medicinal aerosol formulations of formoterol does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicinal aerosol formulations of formoterol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal aerosol formulations of formoterol will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-993749